Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.
Govt prioritising lower denomination notes and digital transactions: Sitharaman
Union Finance Minister Nirmala Sitharaman emphasized the government’s focus on promoting lower denomination currency and increasing digital transaction awareness. With the Rs 2000 note nearly
May 31, 2025